UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 95

Sortiert nach

Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT

Oncoimmunology, 2019-07, Vol.8 (7), p.1593805

2019

Volltextzugriff (PDF)

Immunotherapy Approaches in HPV-Associated Head and Neck Cancer

Cancers, 2021-12, Vol.13 (23), p.5889

2021

Volltextzugriff (PDF)

Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients

Clinical cancer research, 2019-10, Vol.25 (19), p.5752-5758

2019

Volltextzugriff (PDF)

Integrating Immunotherapy into Multimodal Treatment of Head and Neck Cancer

Cancers, 2023-01, Vol.15 (3), p.672

2023

Volltextzugriff (PDF)

Targeting NEDDylation as a Novel Approach to Improve the Treatment of Head and Neck Cancer

Cancers, 2021-06, Vol.13 (13), p.3250

2021

Volltextzugriff (PDF)

Shared Gene Expression and Immune Pathway Changes Associated with Progression from Nevi to Melanoma

Cancers, 2021-12, Vol.14 (1), p.3

2021

Volltextzugriff (PDF)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer

Cancers, 2020-06, Vol.12 (6), p.1537

2020

Volltextzugriff (PDF)

Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions

JCI insight, 2021-09, Vol.6 (17)

2021

Volltextzugriff (PDF)

A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer

Cancers, 2022-05, Vol.14 (11), p.2639

2022

Volltextzugriff (PDF)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer

Cancers, 2022-05, Vol.14 (10), p.2355

2022

Volltextzugriff (PDF)

Randomized Crossover Trial Evaluating Detoxification of Tobacco Carcinogens by Broccoli Seed and Sprout Extract in Current Smokers

Cancers, 2022-04, Vol.14 (9), p.2129

2022

Volltextzugriff (PDF)

Precision medicine: Sustained response to erdafitinib in FGFR2‐mutant, multiply recurrent ameloblastoma

Cancer reports, 2022-10, Vol.5 (10), p.n/a

2022

Volltextzugriff (PDF)

Clinical Study of Aspirin and Zileuton on Biomarkers of Tobacco-Related Carcinogenesis in Current Smokers

Cancers, 2022-06, Vol.14 (12), p.2893

2022

Volltextzugriff (PDF)

NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer

Cancers, 2021-06, Vol.13 (12), p.2882

2021

Volltextzugriff (PDF)

Clinical trials optimizing investigator and self‐collection of buccal cells for RNA yield

Laryngoscope investigative otolaryngology, 2021-02, Vol.6 (1), p.116-121

2021

Volltextzugriff (PDF)

Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals

Clinical cancer research, 2018-01, Vol.24 (1), p.62-72

2018

Volltextzugriff (PDF)

A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab

Biomarker research, 2019-07, Vol.7 (1), p.14-11, Article 14

2019

Volltextzugriff (PDF)

Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer

Cancer research (Chicago, Ill.), 2022-09, Vol.82 (17), p.3188-3188

2022

Volltextzugriff (PDF)

Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer

Cancer research (Chicago, Ill.), 2022-09, Vol.82 (17), p.3187-3187

2022

Volltextzugriff (PDF)

673 FIERCE-HN: a multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A763-A763

2023

Volltextzugriff (PDF)

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma

The Journal of clinical investigation, 2016-04, Vol.126 (4), p.1606-1606

2016

Volltextzugriff (PDF)

Drug repurposing from an academic perspective

Drug discovery today. Therapeutic strategies, 2011-01, Vol.8 (3), p.61-69

2011

Volltextzugriff (PDF)

Author Correction: Head and neck squamous cell carcinoma

Nature reviews. Disease primers, 2023-01, Vol.9 (1), p.4-4, Article 4

2023

Volltextzugriff (PDF)

Institute for Comprehensive Cancer Care Services: The Centers for Medicare & Medicaid Services Will Pay for Patient Navigation—Now What?

Oncology issues, 2024-04, Vol.39 (2), p.54-63

2024

Volltextzugriff (PDF)

674 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A764-A764

2023

Volltextzugriff (PDF)

1 – 25 von 95

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(89)
Mit Volltextzugriff
(91)

Publikationsform

Sprache

Englisch
(95)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT

Immunotherapy Approaches in HPV-Associated Head and Neck Cancer

Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients

Integrating Immunotherapy into Multimodal Treatment of Head and Neck Cancer

Targeting NEDDylation as a Novel Approach to Improve the Treatment of Head and Neck Cancer

Shared Gene Expression and Immune Pathway Changes Associated with Progression from Nevi to Melanoma

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer

Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions

A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer

Randomized Crossover Trial Evaluating Detoxification of Tobacco Carcinogens by Broccoli Seed and Sprout Extract in Current Smokers

Precision medicine: Sustained response to erdafitinib in FGFR2‐mutant, multiply recurrent ameloblastoma

Clinical Study of Aspirin and Zileuton on Biomarkers of Tobacco-Related Carcinogenesis in Current Smokers

NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer

Clinical trials optimizing investigator and self‐collection of buccal cells for RNA yield

Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals

A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab

Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer

Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer

673 FIERCE-HN: a multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma

Drug repurposing from an academic perspective

Author Correction: Head and neck squamous cell carcinoma

Institute for Comprehensive Cancer Care Services: The Centers for Medicare & Medicaid Services Will Pay for Patient Navigation—Now What?

674 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients

Aktive Filter

Suchergebnisse filtern